Osborne Clarke has advised Bone Therapeutics SA on its successful fund raising of EUR 8.5 million in gross proceeds through a EUR 5 million private placement of new shares via an accelerated bookbuild offering, and a EUR 3.5 million non-dilutive subordinated bond placement.
Bone Therapeutics is a leading biotech company listed on Euronext Brussels and Paris focused on the development of innovative cell and biological therapies to address high unmet medical needs in orthopaedics and bone diseases. Bone Therapeutics’ core technology is based on its off-the-shelf allogeneic cell therapy platform (ALLOB) which uses a unique, proprietary approach to bone regeneration, which turns undifferentiated stem cells from healthy donors into bone-forming cells.
The team of Osborne Clarke in Belgium was led by David Haex (Picture) and Hadrien Chef and included Tonya Aelbrecht, Violette Keppenne, Laurent Donnay de Casteau and Olivier Lambillon. The Belgian team was also supported by Sophie Jouniaux (Tax, OC France).
Involved fees earner: Tonya Aelbrecht – Osborne Clarke; Hadrien Chef – Osborne Clarke; Laurent Donnay de Casteau – Osborne Clarke; David Haex – Osborne Clarke; Violette Keppenne – Osborne Clarke; Olivier Lambillon – Osborne Clarke;
Law Firms: Osborne Clarke;
Clients: Bone Therapeutics SA;